Regulatory and Safety Aspects of Cell and Gene Therapy


Cell therapy products require a variety of safety considerations. Stem cell and gene products are heterogeneous substances. There are several areas that particularly need to be addressed as it is quite different from that of pharmaceuticals. These range from creating batch consistency, product stability to product safety, strength and efficacy through pre-clinical, clinical studies and marketing authorization. This review summarizes the existing regulations/guidelines in US, EU, India, and the associated challenges in developing SCBP with emphasis on clinical aspect.


  • Guidelines of cell therapy
  • safety precautions

Related Conference of Regulatory and Safety Aspects of Cell and Gene Therapy

May 03-04, 2023

16th World Congress on Stem Cell Research

Paris, France
May 03-04, 2023

Global Conference on Cell and Gene Therapy

Paris, France
June 08-09, 2023

10th World Congress on Epigenetics and Chromosome

Valencia, Spain
August 21-22, 2023

6th Annual Conference on Stem Cell and Regenerative Medicine

Frankfurt, Germany
September 25-26, 2023

19th Global Summit on Stem Cell & Regenerative Medicine

Zurich, Switzerland
October 19-20, 2023

5th Annual summit on Cell Signaling and Cancer Therapy

Montreal, Canada
November 08-09, 2023

4th Experts Meeting on Plant, Cellular and Molecular Biology

Budapest, Hungary
December 07-08, 2023

17th International Conference on Genomics & Pharmacogenomics

San Francisco, USA

Regulatory and Safety Aspects of Cell and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in